Patent ID: 8066989

Claim:
A method of substantially reducing or avoiding a graft versus host disease during treatment of tumor growth and metastasis in a mammal, said method comprising in vivo administering allogeneic effector cells together with trifunctional bispecific antibodies having the following properties: a) binding to CD3 on a T cell b) binding to at least one antigen on a tumor cell c) binding via their Fc portion to Fc receptor positive cells, d) having one of the following subclass combinations: i) rat-IgG2b/mouse-IgG2a, ii) rat-IgG2b/mouse-IgG2b, iii) rat-IgG2b/human-IgG1, iv) mouse-[VH-CH1, VL-CL]-human-IgGI/rat-[VH-CH1, VL-CL]-human-IgG1[hinge]-human-IgG3*-[CH2-CH3] wherein*=caucasian allotypes G3m(b+g)=no binding to protein A, wherein said allogeneic effector cells are Fc receptor positive cells and are a combination of lymphoid cells comprising T cells, NK cells and B cells and myeloid cells comprising monocytes and optionally additionally macrophages or dendritic cells or a combination thereof, whereby said tumor growth and metastasis is treated and graft versus host disease is substantially reduced or avoided in said mammal.